Please use this identifier to cite or link to this item: http://hdl.handle.net/10397/111700
PIRA download icon_1.1View/Download Full Text
DC FieldValueLanguage
dc.contributorDepartment of Biomedical Engineering-
dc.creatorDeng, R-
dc.date.accessioned2025-03-13T02:22:07Z-
dc.date.available2025-03-13T02:22:07Z-
dc.identifier.issn2273-1709-
dc.identifier.urihttp://hdl.handle.net/10397/111700-
dc.description2024 6th International Conference on Biotechnology and Biomedicine (ICBB 2024), 29-31 March 2024, Wuhan, Chinaen_US
dc.language.isoenen_US
dc.publisherEDP Sciencesen_US
dc.rights© The Authors, published by EDP Sciences. This is an open access article distributed under the terms of the Creative Commons Attribution License 4.0 (https://creativecommons.org/licenses/by/4.0/).en_US
dc.rightsThe following publication Deng, R. (2024). p53 contributes to the chemotherapeutic drug doxorubicininduced cell death in colorectal cancer cell line HCT116. BIO Web Conf., 111, 01004 is available at https://doi.org/10.1051/bioconf/202411101004.en_US
dc.titlep53 contributes to the chemotherapeutic drug doxorubicininduced cell death in colorectal cancer cell line HCT116en_US
dc.typeConference Paperen_US
dc.identifier.volume111-
dc.identifier.doi10.1051/bioconf/202411101004-
dcterms.abstractDoxorubicin is a commonly used chemotherapy drug for cancer treatment, but its effectiveness varies across different cancer types. p53 is a key factor involved in cell death induced by therapeutic agents. It can be upregulated by Doxorubicin and have a function of apoptosis. To have a further study of the mechanism between p53 and Doxorubicin, we investigated whether p53 play a role in the doxorubicininduced cell death in the colorectal cancer line HCT116. Our finding revealed that p53 was upregulated in HCT116 cells when treated with doxorubicin, and knockdown of p53 decreased the sensitivity of HCT116 cells to doxorubicin. These results suggest that p53 plays an important role in doxorubicin-induced cell death in HCT116 cells, which could contribute to more effective treatment approaches.-
dcterms.accessRightsopen accessen_US
dcterms.bibliographicCitationBIO web of conferences, 2024, v. 111, 01004-
dcterms.isPartOfBIO web of conferences-
dcterms.issued2024-
dc.identifier.scopus2-s2.0-85196210311-
dc.relation.conferenceInternational Conference on Biotechnology and Biomedicine [ICBB]-
dc.identifier.eissn2117-4458-
dc.identifier.artn01004-
dc.description.validate202503 bcch-
dc.description.oaVersion of Recorden_US
dc.identifier.FolderNumberOA_Othersen_US
dc.description.fundingSourceSelf-fundeden_US
dc.description.pubStatusPublisheden_US
dc.description.oaCategoryCCen_US
Appears in Collections:Conference Paper
Files in This Item:
File Description SizeFormat 
bioconf_icbb2024_01004.pdf332.29 kBAdobe PDFView/Open
Open Access Information
Status open access
File Version Version of Record
Access
View full-text via PolyU eLinks SFX Query
Show simple item record

Page views

6
Citations as of Apr 14, 2025

Downloads

2
Citations as of Apr 14, 2025

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.